title: Cardiac gene therapy with SERCA2a: from bench to bedside.
abstract: While progress in conventional treatments is making steady and incremental gains to reduce mortality associated with heart failure, there remains a need to explore potentially new therapeutic approaches. Heart failure induced by different etiologies such as coronary artery disease, hypertension, diabetes, infection, or inflammation results generally in calcium cycling dysregulation at the myocyte level. Recent advances in understanding of the molecular basis of these calcium cycling abnormalities, together with the evolution of increasingly efficient gene transfer technology, have placed heart failure within reach of gene-based therapy. Furthermore, the recent successful completion of a phase 2 trial targeting the sarcoplasmic reticulum calcium pump (SERCA2a) ushers in a new era for gene therapy for the treatment of heart failure. This article is part of a Special Section entitled "Special Section: Cardiovascular Gene Therapy".
authors.affiliation: Gwathmey Inc, Cambridge, MA 2038, USA. roger.hajjar@mssm.edu
authors.forename: Judith K
authors.initials: JK
authors.lastname: Gwathmey
authors.forename: Alexan I
authors.initials: AI
authors.lastname: Yerevanian
authors.forename: Roger J
authors.initials: RJ
authors.lastname: Hajjar
mesh_terms: D000818:Animals; D015316:Genetic Therapy / Q000379:methods*; D006333:Heart Failure / Q000628:therapy; D006801:Humans; D008954:Models, Biological; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases / Q000235:genetics*
chemical_list: D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases